Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Finally Reveals €9.6B Nycomed Acquisition; Sheds Dermatology Business, But Otherwise Set On Retention

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceuticals Co. Ltd. finally confirmed it will acquire emerging markets player Nycomed AS. Takeda's initial denial of a $12 billion acquisition proved partially correct, instead agreeing to pay €9.6 billion ($13.7 billion) for the Swiss company, excluding its U.S dermatology business

You may also be interested in...

Takeda’s Strategic Run Up To Nycomed

With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.

Takeda’s Vaccine Business Aims High, Led By Former Gates Foundation Vaccine Director

Established in January 2012 on the foundation of Takeda’s long-standing domestic pediatric vaccine business, the new initiative will be global in scale, building on the territorial gains from the Nycomed acquisition, and led by a seasoned player.

Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?

TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts